)
Novacyt (ALNOV) investor relations material
Novacyt H1 2026 TU earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Delivered strong H1 2026 performance with 18% year-over-year revenue growth to approximately £11.6 million, driven by organic momentum and the integration of Southern Cross Diagnostics.
All geographic regions reported revenue growth, with the Americas exceeding 30% and Asia-Pacific around 22%.
Continued progress on restructuring, expected to yield up to £4.0 million in annualized cost savings.
Financial highlights
Group statutory revenue rose 18% year-over-year to about £11.6 million for H1 2026.
Underlying revenue, excluding SCD, increased by 9%.
Instrumentation segment achieved 30% year-over-year revenue growth; Clinical segment grew over 20%.
SCD contributed approximately £1.8 million in revenue post-acquisition.
Cash balance at 30 June 2026 was £8.9 million, down from £19.1 million at year-end 2025, reflecting acquisition outflows.
Outlook and guidance
Restructuring program is expected to deliver significant cost savings and extend cash runway.
IVDR accreditation for the new DPYD kit anticipated in the coming months.
- Revenue up 4% to GBP 20m, margins strong, and double-digit growth targeted for 2026.ALNOV
H2 20251 Jul 2026 - Revenue up 85% to £19.6m, with strong cash and new launches planned for 2025.ALNOV
H2 20241 Jul 2026 - Acquisition delivers immediate profitability, expanded portfolio, and direct market access.ALNOV
Status update8 Apr 2026 - Revenue up 4% to £20.0m in 2025, with strong cash and growth in Instrumentation and APAC.ALNOV
H2 2025 TU21 Jan 2026 - Revenue up 209% to £10.3m, DHSC dispute resolved, and strong cash position supports growth.ALNOV
H1 202420 Jan 2026 - EBITDA loss narrowed to £4.1m on £9.8m revenue, with strong growth in reproductive health.ALNOV
H1 202530 Sep 2025 - Liquidity contract activity increased share holdings to 104,002 and set a €5.00 buyback cap.ALNOV
Q2 2025 TU28 Jul 2025 - FY 2024 revenue up 85% to £19.6m, with strong Reproductive Health and cost efficiencies.ALNOV
H2 2024 TU6 Jun 2025
Next Novacyt earnings date
Next Novacyt earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
Frequently asked questions
Explore our global coverage
)
)